| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lantheus Holdings Inc. | NM-01 - (PELICAN) | Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Lantheus Holdings Inc. | 1095 - ARROW | Prostate Cancer | Phase 2 | Ongoing | Oral | Oncology |
| Legend Biotech Corporation | (CARTITUDE-6) | Newly-diagnosed multiple myeloma (MM) | Phase 3 | Enrollment Conclusion | Intravenous | Oncology |
| Legend Biotech Corporation | Ciltacabtagene autoleucel - (CARTIFAN-1) | Relapsed/Refractory Multiple Myeloma (R/R MM) | Phase 2 | Ongoing | Intravenous infusion | Oncology |
| LeonaBio Inc Com (New) | Fosgonimeton (ATH-1017) - (LIFT-AD) | Alzheimer’s disease | Phase 2/3 | Data Released | Intravenous | Neurology |
| LeonaBio Inc Com (New) | Fosgonimeton - (OLEX) | Alzheimer's Disease | Phase 2/3 | Trial Planned | Oral | Neurology |
| LeonaBio Inc Com (New) | ATH-1017 - (ACT-AD) | Mild-to-moderate Alzheimer's disease | Phase 2 | Data Released | Intravenous | Neurology |
| LeonaBio Inc Com (New) | Fosgonimeton (ATH-1017) - (SHAPE) | Parkinson’s disease dementia | Phase 2 | Data Released | Intravenous | Neurology |